Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Single-Dose Intravesical Epirubicin in Bladder Cancer
NCT05084586Unknown
- Sponsor
- Ankara Training and Research Hospital
- Start
- Oct 2019
- Primary completion
- Oct 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of epirubicin in bladder cancer (2 arms), sponsored by Ankara Training and Research Hospital. Primary endpoint: Rate of Tumor Recurrence and Progression at 1 year. Status: unknown.
02
Drugs
epirubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05084586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084586.